top of page


Chaeum Premium 3




Two syringes × 1.1 ml, four needles per pack

Needle size: 25G x 4 needles


Chaeum Premium is a series of dermal fillers containing highly cross-linked hyaluronic acid (HA). The unique cross-linking technology used in the production of Chaeum Premium fillers provides a single-phase and uniform structure of the HA. Exceptional purity is obtained by prolonged dialysis of hyaluronic acid after the cross-linking reaction. The regular and dense gel structure ensures a smooth and even distribution of the product during injection and a natural-looking effect.

The Chaeum Premium line of fillers based on cross-linked hyaluronic acid is presented in 4 types with a number sequence from 1 to 4.

Chaeum Premium 3 is used to correct medium and deep wrinkles, lip augmentation, and facial volumization. The filler has a high HA cross-linking rate of 3 out of 4 and is injected into the middle and deep dermis.

Strengths of Chaeum Premium 3:

  • High purity minimizes post-injection inflammation.
  • Low BDDE and protein loads reduce the risk of allergic reactions
  • Advanced product safety due to the extended dialysis for removal of BDDE residues
  • Less painful and minimal injury risk
  • Regular and dense gel structure ensures even distribution of the filler and a natural-looking effect

Scope of Chaeum Premium 3:

Chaeum Premium 3 is designed to fill expression lines in the middle and deep dermis.

  • Glabellar and forehead lines
  • Nasolabial folds
  • Chin wrinkles
  • Lip augmentation
  • Facial volumization (forehead, chin, and cheekbone areas)
  • Nose bridge/ridge improvement

Effect Duration:

  • Depend on the skin type and practitioner injecting method

Product composition:

Cross-linked Hyaluronic Acid of 20 mg per ml

Lidocaine of 3 mg per ml

Chaeum Premium 3 Product Information

2 syringes × 1.1 ml, four needles per pack

Needle size: 25G x 4 needles

Injection Depth: middle and deep dermis

Storage: Room temperature

Shelf Life: 24 months from manufacturing date

Manufacturer: Hugel Pharma Co., Ltd., South Korea

    bottom of page